Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial 50S ribosomal subunit is the larger component of the prokaryotic 70S ribosome, primarily composed of 23S ribosomal RNA (rRNA), 5S rRNA, and approximately 33 ribosomal proteins (PubMed: PMID 11514518). Its fundamental biological role is to catalyze the peptidyl transferase reaction, which forms peptide bonds between amino acids during translation, and to provide a channel for the nascent polypeptide to exit the ribosome. This subunit is a major target for various classes of antibiotics because of the structural differences between prokaryotic and eukaryotic ribosomes, allowing for selective toxicity. Clindamycin, a lincosamide antibiotic, binds specifically to the 23S rRNA component of the 50S subunit at the peptidyl transferase center (StatPearls: Clindamycin, 2023). This binding prevents the attachment of aminoacyl-tRNA and inhibits the translocation step, effectively halting bacterial protein synthesis. Clinically, targeting the 50S subunit is essential for treating infections caused by Gram-positive cocci and anaerobic bacteria, though resistance mediated by rRNA methylation (erm genes) remains a significant therapeutic challenge (PubMed: PMID 15544330).
Clindamycin binds to the 50S ribosomal subunit of susceptible bacteria, specifically at the 23S rRNA component within the peptidyl transferase center, which inhibits the formation of peptide bonds and prevents the translocation of the peptide chain, thereby halting bacterial protein synthesis (StatPearls: Clindamycin, 2023; PubMed: PMID 11514518).
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 50S ribosomal subunit (50S subunit) (50S subunit).